Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Forum on Immunopathological Diseases and Therapeutics
SJR: 0.164 SNIP: 0.041 CiteScore™: 0.18

ISSN Imprimer: 2151-8017
ISSN En ligne: 2151-8025

Archives: Volume 1, 2010 to Volume 7, 2016

Forum on Immunopathological Diseases and Therapeutics

DOI: 10.1615/ForumImmunDisTher.2014011238
pages 197-212

Structure and Biological Activity of Botulinum Neurotoxins and Application to Cancer Therapy

Kei Roger Aoki
Neurotoxin Research Program, Discovery Research Biological Sciences, Allergan, Inc., Irvine, California
Ester Fernandez-Salas
Department of Pathology, School of Medicine, University of Michigan, Ann Arbor, Michigan

RÉSUMÉ

Botulinum neurotoxin (BoNT) has historically been studied as the botulism-causing protein produced by the anaerobic bacillus, Clostridium botulinum. However, research interest in BoNT has recently shifted toward the mechanisms by which it can be utilized to decipher basic neuronal biology, treat neuromuscular disorders and pain, and be used as an anticancer treatment. BoNT has been shown to inhibit the release of neurotransmitters and factors required for tumor growth and maintenance, altering the tumor microenvironment. Treatment with BoNT can also enhance the delivery of chemotherapeutic agents, serve as an adjuvant to cancer chemotherapy, mitigate cancer-related side effects (i.e., pain and excess saliva), and potentiate the effects of radiotherapy. Most recently, work with BoNT has focused on the direct effects of the toxin in tumor cells. Through protein retargeting and recombinant technology, the activity of BoNT can be specifically delivered to cancer cells. This review summarizes the variety of ways in which BoNT has been used as an adjuvant for cancer therapy, discusses the potential mechanisms that describe how BoNT may affect growth and apoptosis of tumor cells, and highlights the promise these new biomolecules have as a safer and more effective anticancer therapeutic.


Articles with similar content:

Nanotechnology-Based Photodynamic Therapy: Concepts, Advances, and Perspectives
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.32, 2015, issue 5
Nitin K. Jain, Goutam Rath, Tarun Garg, Amit Kumar Goyal
Emerging Role of Vesicular Carriers for Therapy of Visceral Leishmaniasis: Conventional versus Novel
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.27, 2010, issue 6
Navneet Kumar, Suresh P. Vyas, Anuradha Dube, Swati Gupta
Pancreatic Cancer: Recent Advances in Nanoformulation-Based Therapies
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.36, 2019, issue 1
Preshita Desai, Jeffrey Wang, Sunil Prabhu, David Ann
Recent Advances in Cancer Stem Cell Targeted Therapy
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 1
Muge Ocal, Hakan Akbulut, Samira Abdi Abgarmi, Merve Besler, Cansu Babahan
Polymeric Immunonanoparticles Mediated Cancer Therapy: Versatile Nanocarriers for Cell-Specific Cargo Delivery
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.35, 2018, issue 1
Niyati S. Acharya, Namdev L. Dhas, Ritu R. Kudarha, Sanjeev R. Acharya